## <i>APOE</i> effect on Alzheimer's disease biomarkers i memory concern

Alzheimer's and Dementia 11, 1417-1429 DOI: 10.1016/j.jalz.2015.03.003

**Citation Report** 

#	Article	IF	CITATIONS
1	Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans. Alzheimer's and Dementia, 2015, 11, 792-814.	0.4	241
2	GWAS of longitudinal amyloid accumulation on <sup>18</sup> F-florbetapir PET in Alzheimer's disease implicates microglial activation gene <i>IL1RAP</i> . Brain, 2015, 138, 3076-3088.	3.7	117
3	General practitioner referrals to memory clinics: are referral criteria delaying the diagnosis of dementia?. Journal of the Royal Society of Medicine, 2016, 109, 410-415.	1.1	2
4	Subjective cognitive decline: The first clinical manifestation of Alzheimer's disease?. Dementia E Neuropsychologia, 2016, 10, 170-177.	0.3	88
5	The Cognitive Change Index as a Measure of Self and Informant Perception of Cognitive Decline: Relation to Neuropsychological Tests. Journal of Alzheimer's Disease, 2016, 51, 1145-1155.	1.2	93
6	Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. JAMA Neurology, 2016, 73, 721.	4.5	235
7	Genome research in pre-dementia stages of Alzheimer's disease. Expert Reviews in Molecular Medicine, 2016, 18, e11.	1.6	13
8	Identifying Multimodal Intermediate Phenotypes Between Genetic Risk Factors and Disease Status in Alzheimer's Disease. Neuroinformatics, 2016, 14, 439-452.	1.5	26
9	Serum high-density lipoprotein is associated with better cognitive function in a cross-sectional study of aging women. International Journal of Neuroscience, 2017, 127, 243-252.	0.8	34
10	Multimodal characterization of older <i>APOE2</i> carriers reveals selective reduction of amyloid load. Neurology, 2017, 88, 569-576.	1.5	50
11	Subjective Cognitive Decline in Preclinical Alzheimer's Disease. Annual Review of Clinical Psychology, 2017, 13, 369-396.	6.3	352
12	State of Play in Alzheimer's Disease Genetics. Journal of Alzheimer's Disease, 2017, 58, 631-659.	1.2	34
13	Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. Alzheimer's and Dementia, 2017, 13, e1-e85.	0.4	213
14	Mining Outcome-relevant Brain Imaging Genetic Associations via Three-way Sparse Canonical Correlation Analysis in Alzheimer's Disease. Scientific Reports, 2017, 7, 44272.	1.6	44
15	Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging, 2017, 60, 92-103.	1.5	70
16	Olfactory identification in subjective cognitive decline and mild cognitive impairment: Association with tau but not amyloid positron emission tomography. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 9, 57-66.	1.2	44
17	Apolipoprotein E e4 Allele Is Associated with Subjective Cognitive Decline: A Meta-Analysis. Neuroepidemiology, 2017, 49, 165-173.	1.1	13
18	Longitudinal Assessment of Self- and Informant-Subjective Cognitive Complaints in a Sample of Healthy Late-Middle Aged Adults Enriched with a Family History of Alzheimer's Disease. Journal of the International Neuropsychological Society, 2017, 23, 617-626.	1.2	17

#	Article	IF	CITATIONS
19	Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer's disease. BMC Medical Genomics, 2017, 10, 29.	0.7	28
20	Implementation of subjective cognitive decline criteria in research studies. Alzheimer's and Dementia, 2017, 13, 296-311.	0.4	375
21	Self-paced learning for multi-modal fusion for alzheimer's disease diagnosis. , 2017, , .		0
22	The Relationship of Brain Amyloid Load and APOE Status to Regional Cortical Thinning and Cognition in the ADNI Cohort. Journal of Alzheimer's Disease, 2017, 59, 1269-1282.	1.2	29
23	Biomarkers for Alzheimer's Disease Diagnosis. Current Alzheimer Research, 2017, 14, 1149-1154.	0.7	180
24	A Bayesian Model for the Prediction and Early Diagnosis of Alzheimer's Disease. Frontiers in Aging Neuroscience, 2017, 9, 77.	1.7	42
25	Prediction of Mild Cognitive Impairment Conversion Using a Combination of Independent Component Analysis and the Cox Model. Frontiers in Human Neuroscience, 2017, 11, 33.	1.0	66
26	Subjective Cognitive Decline and Alzheimer's Disease Spectrum Disorder. Dementia and Neurocognitive Disorders, 2017, 16, 40.	0.4	18
27	Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE ε4 genotype. Brain, 2018, 141, 1828-1839.	3.7	99
28	Memory concerns in the early Alzheimer's disease prodrome: Regional association with tau deposition. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 322-331.	1.2	22
29	Volumetric comparison of hippocampal subfields extracted from 4-minute accelerated vs. 8-minute high-resolution T2-weighted 3T MRI scans. Brain Imaging and Behavior, 2018, 12, 1583-1595.	1.1	13
30	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	1.3	215
31	Risk factors for amyloid positivity in older people reporting significant memory concern. Comprehensive Psychiatry, 2018, 80, 126-131.	1.5	10
32	Exploring <i>APOE</i> genotype effects on Alzheimer's disease risk and amyloid β burden in individuals with subjective cognitive decline: The FundacioACE Healthy Brain Initiative (FACEHBI) study baseline results. Alzheimer's and Dementia, 2018, 14, 634-643.	0.4	33
33	Rare variants in the splicing regulatory elements of EXOC3L4 are associated with brain glucose metabolism in Alzheimer's disease. BMC Medical Genomics, 2018, 11, 76.	0.7	12
34	Clinical dementia severity associated with ventricular size is differentially moderated by cognitive reserve in men and women. Alzheimer's Research and Therapy, 2018, 10, 89.	3.0	11
35	Association Between Midlife Risk Factors and Late-Onset Epilepsy. JAMA Neurology, 2018, 75, 1375.	4.5	81
36	Subjective Cognitive Decline and APOE ɛ4: A Systematic Review. Journal of Alzheimer's Disease, 2018, 65, 303-320.	1.2	32

#	Article	IF	CITATIONS
37	The Relation Between Brain Amyloid Deposition, Cortical Atrophy, and Plasma Biomarkers in Amnesic Mild Cognitive Impairment and Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 175.	1.7	48
38	Spatial navigation deficits — overlooked cognitive marker for preclinical Alzheimer disease?. Nature Reviews Neurology, 2018, 14, 496-506.	4.9	293
39	Synergistic interaction between APOE and family history of Alzheimer's disease on cerebral amyloid deposition and glucose metabolism. Alzheimer's Research and Therapy, 2018, 10, 84.	3.0	21
40	Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results. Alzheimer's Research and Therapy, 2018, 10, 76.	3.0	87
41	Default Mode Network Connectivity Moderates the Relationship Between the APOE Genotype and Cognition and Individualizes Identification Across the Alzheimer's Disease Spectrum. Journal of Alzheimer's Disease, 2019, 70, 843-860.	1.2	18
42	Prediction of fast decline in amyloid positive mild cognitive impairment patients using multimodal biomarkers. NeuroImage: Clinical, 2019, 24, 101941.	1.4	21
43	Targeted genetic analysis of cerebral blood flow imaging phenotypes implicates the INPP5D gene. Neurobiology of Aging, 2019, 81, 213-221.	1.5	30
44	Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers. JAMA Network Open, 2019, 2, e197978.	2.8	142
45	Genome-wide association analysis of hippocampal volume identifies enrichment of neurogenesis-related pathways. Scientific Reports, 2019, 9, 14498.	1.6	22
46	Visual short-term memory binding deficit with age-relatedÂhearing loss in cognitively normal older adults. Scientific Reports, 2019, 9, 12600.	1.6	10
47	White matter alterations in earlyâ€stage Alzheimer's disease: A tractâ€specific study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 576-587.	1.2	50
48	Classification of Early and Late Mild Cognitive Impairment Using Functional Brain Network of Resting-State fMRI. Frontiers in Psychiatry, 2019, 10, 572.	1.3	41
49	Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell, 2019, 179, 312-339.	13.5	1,675
50	Dual-Model Radiomic Biomarkers Predict Development of Mild Cognitive Impairment Progression to Alzheimer's Disease. Frontiers in Neuroscience, 2018, 12, 1045.	1.4	46
51	Chromatographic fingerprint based on serially coupled columns combined with multiple-component quantitation with a single reference standard for quality evaluation of Shen–Zhi–Ling oral liquid. Analytical Methods, 2019, 11, 367-374.	1.3	5
52	Anxiety correlates with cortical surface area in subjective cognitive decline: APOE ε4 carriers versus APOE ε4 non-carriers. Alzheimer's Research and Therapy, 2019, 11, 50.	3.0	26
53	Impaired memory-guided attention in asymptomatic APOE4 carriers. Scientific Reports, 2019, 9, 8138.	1.6	11
54	Prediction of Alzheimer's Pathological Changes in Subjective Cognitive Decline Using the Self-report Questionnaire and Neuroimaging Biomarkers. Dementia and Neurocognitive Disorders, 2019, 18, 19.	0.4	16

#	Article	IF	CITATIONS
55	Risk classification for conversion from mild cognitive impairment to Alzheimer's disease in primary care. Psychiatry Research, 2019, 278, 19-26.	1.7	12
56	The Contribution of Genetic Factors to Cognitive Impairment and Dementia: Apolipoprotein E Gene, Gene Interactions, and Polygenic Risk. International Journal of Molecular Sciences, 2019, 20, 1177.	1.8	39
57	Subjective Cognitive Impairment in 55-65-Year-Old Adults Is Associated with Negative Affective Symptoms, Neuroticism, and Poor Quality of Life. Journal of Alzheimer's Disease, 2019, 67, 1367-1378.	1.2	28
58	Neuroimaging in aging and neurologic diseases. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 191-227.	1.0	25
59	The use of back propagation neural networks and 18F-Florbetapir PET for early detection of Alzheimer's disease using Alzheimer's Disease Neuroimaging Initiative database. PLoS ONE, 2019, 14, e0226577.	1.1	18
60	Subjective cognitive decline and rates of incident Alzheimer's disease and non–Alzheimer's disease dementia. Alzheimer's and Dementia, 2019, 15, 465-476.	0.4	232
61	Subjective cognitive decline: preclinical manifestation of Alzheimer's disease. Neurological Sciences, 2019, 40, 41-49.	0.9	50
62	Prevalence and risk of progression of preclinical Alzheimer's disease stages: a systematic review and meta-analysis. Alzheimer's Research and Therapy, 2019, 11, 7.	3.0	87
63	Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers. Alzheimer's and Dementia, 2019, 15, 232-244.	0.4	198
64	Subjective memory complaints predict baseline but not future cognitive function over three years: results from the Western Australia Memory Study. International Psychogeriatrics, 2019, 31, 513-525.	0.6	13
65	Modified ketogenic diet is associated with improved cerebrospinal fluid biomarker profile, cerebral perfusion, and cerebral ketone body uptake in older adults at risk for Alzheimer's disease: a pilot study. Neurobiology of Aging, 2020, 86, 54-63.	1.5	136
66	Brain Imaging Genomics: Integrated Analysis and Machine Learning. Proceedings of the IEEE, 2020, 108, 125-162.	16.4	100
67	Hypergraph based multi-task feature selection for multimodal classification of Alzheimer's disease. Computerized Medical Imaging and Graphics, 2020, 80, 101663.	3.5	72
68	POINT/COUNTER-POINT—Beyond the headlines: the actual evidence that traumatic brain injury is a risk factor for later-in-life dementia. Archives of Clinical Neuropsychology, 2020, 35, 123-127.	0.3	12
69	Multi-modal neuroimaging feature selection with consistent metric constraint for diagnosis of Alzheimer's disease. Medical Image Analysis, 2020, 60, 101625.	7.0	99
70	Dysregulated Fc gamma receptor–mediated phagocytosis pathway in Alzheimer's disease: network-based gene expression analysis. Neurobiology of Aging, 2020, 88, 24-32.	1.5	28
71	Association of blood-based transcriptional risk scores with biomarkers for Alzheimer disease. Neurology: Genetics, 2020, 6, e517.	0.9	13
72	Advancing combination therapy for Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12073.	1.8	21

ARTICLE IF CITATIONS Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration. 73 4.4 33 Molecular Neurodegeneration, 2020, 15, 57. Volumetric GWAS of medial temporal lobe structures identifies an ERC1 locus using ADNI 74 1.5 high-resolution T2-weighted MRI data. Neurobiology of Aging, 2020, 95, 81-93. 75 Neural network applications in medicine., 2020, , 183-206. 2 MicroRNA-138 promotes neuroblastoma SH-SY5Y cell apoptosis by directly targeting DEK in Alzheimer's disease cell model. BMC Neuroscience, 2020, 21, 33. Genomeâ€wide transcriptome analysis identifies novel dysregulated genes implicated in Alzheimer's 77 0.4 23 pathology. Alzheimer's and Dementia, 2020, 16, 1213-1223. Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease. 4.4 Molecular Neurodegeneration, 2020, 15, 55. InÂvivo staging of regional amyloid deposition predicts functional conversion in the preclinical and 79 1.5 21 prodromal phases of Alzheimer's disease. Neurobiology of Aging, 2020, 93, 98-108. CSF biomarkers in Olmsted County. Neurology, 2020, 95, e256-e267. 1.5 80 14 Functional connectivity between the entorhinal and posterior cingulate cortices underpins 81 1.5 19 navigation discrepancies in at-risk Alzheimer's disease. Neurobiology of Aging, 2020, 90, 110-118. The characterisation of subjective cognitive decline. Lancet Neurology, The, 2020, 19, 271-278. Î<sup>2</sup>-amyloid: The known unknowns. Ageing Research Reviews, 2021, 65, 101212. 83 5.027 Sex modifies APOE  $\hat{I}\mu4$  dose effect on brain tau deposition in cognitively impaired individuals. Brain, 2021, 3.7 84 144, 3201-3211. Effects of Combined Physical Activity and Cognitive Training on Cognitive Function in Older Adults with Subjective Cognitive Decline: A Systematic Review and Meta-Analysis of Randomized Controlled 85 0.5 6 Trials. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-14. Glucose metabolism in the right middle temporal gyrus could be a potential biomarker for subjective cognitive decline: a study of a Han population. Alzheimer's Research and Therapy, 2021, 13, 74. Synergistic Effects of APOE and CLU May Increase the Risk of Alzheimer's Disease: Acceleration of Atrophy in the Volumes and Shapes of the Hippocampus and Amygdala. Journal of Alzheimer's Disease, 87 1.2 13 2021, 80, 1311-1327. Distinct Profile Differences in Subjective Cognitive Decline in the General Public Are Associated with Metacognition, Negative Affective Symptoms, Neuroticism, Stress, and Poor Quality of Life. Journal of Alzheimer's Disease, 2021, 80, 1231-1242. Impaired cerebral vascular and metabolic responses to parametric N-back tasks in subjective cognitive 89 2.4 7 decline. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 2743-2755. Machine learning based on the multimodal connectome can predict the preclinical stage of 90 2.3 Alzheimer's disease: a preliminary study. European Radiology, 2022, 32, 448-459.

#	Article	IF	CITATIONS
91	Rare CASP6N73T variant associated with hippocampal volume exhibits decreased proteolytic activity, synaptic transmission defect, and neurodegeneration. Scientific Reports, 2021, 11, 12695.	1.6	8
92	Topographical patterns of whole-brain structural alterations in association with genetic risk, cerebrospinal fluid, positron emission tomography biomarkers of Alzheimer's disease, and neuropsychological measures. Clinical and Translational Imaging, 2021, 9, 439-497.	1.1	0
93	Computer-aided diagnosis of Alzheimer's disease by MRI analysis and evolutionary computing. Research on Biomedical Engineering, 2021, 37, 455-483.	1.5	2
94	Predictability of polygenic risk score for progression to dementia and its interaction with APOE ε4 in mild cognitive impairment. Translational Neurodegeneration, 2021, 10, 32.	3.6	11
97	Women Exhibit Lower Global Left Frontal Cortex Connectivity Among Cognitively Unimpaired Elderly Individuals: A Pilot Study from SILCODE. Journal of Alzheimer's Disease, 2021, 83, 653-663.	1.2	4
99	Motoric cognitive risk syndrome: Integration of two early harbingers of dementia in older adults. Ageing Research Reviews, 2020, 58, 101022.	5.0	48
101	Fine-mapping of the human leukocyte antigen locus as a risk factor for Alzheimer disease: A case–control study. PLoS Medicine, 2017, 14, e1002272.	3.9	67
102	Noninvasive Brain Stimulation Enhances Memory Acquisition and Is Associated with Synaptoneurosome Modification in the Rat Hippocampus. ENeuro, 2019, 6, ENEURO.0311-19.2019.	0.9	7
103	Integrated Genomic Analysis Revealed Associated Genes for Alzheimer's Disease in APOE4 Non-Carriers. Current Alzheimer Research, 2019, 16, 753-763.	0.7	9
104	Cognitive Reserve, Brain Reserve, APOE ɛ4, and Cognition in Individuals with Subjective Cognitive Decline in the SILCODE Study. Journal of Alzheimer's Disease, 2020, 76, 249-260.	1.2	9
105	Paraoxonase Role in Human Neurodegenerative Diseases. Antioxidants, 2021, 10, 11.	2.2	26
106	Structure and Feature Based Graph U-Net for Early Alzheimer's Disease Prediction. Lecture Notes in Computer Science, 2021, , 93-104.	1.0	2
107	Impairment of Episodic-Specific Autobiographical Memory in Individuals with Subjective Cognitive Decline and in Patients with Prodromal or Mild Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 84, 1485-1496.	1.2	5
109	Depression and APOEε4 Status in Individuals with Subjective Cognitive Decline: A Meta-Analysis. Psychiatry Investigation, 2020, 17, 858-864.	0.7	7
110	The Influence of Amyloid Burden on Cognitive Decline over 2 years in Older Adults with Subjective Cognitive Decline: A Prospective Cohort Study. Dementia and Geriatric Cognitive Disorders, 2021, 50, 437-445.	0.7	7
111	Dysregulated expression levels of APH1B in peripheral blood are associated with brain atrophy and amyloid-β deposition in Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 183.	3.0	13
112	Genetic variation affecting exon skipping contributes to brain structural atrophy in Alzheimer's disease. AMIA Summits on Translational Science Proceedings, 2018, 2017, 124-131.	0.4	6
113	Regional brain atrophy and cognitive decline depend on definition of subjective cognitive decline. NeuroImage: Clinical, 2022, 33, 102923.	1.4	16

#	Article	IF	CITATIONS
114	A Neuropsychological Perspective on Defining Cognitive Impairment in the Clinical Study of Alzheimer's Disease: Towards a More Continuous Approach. Journal of Alzheimer's Disease, 2022, 86, 511-524.	1.2	5
115	Identification of subjective cognitive decline due to Alzheimer's disease using multimodal MRI combining with machine learning. Cerebral Cortex, 2023, 33, 557-566.	1.6	11
116	A Systematic Review of Neuroimaging Studies Comparing Individuals with Subjective Cognitive Decline to Healthy Controls. Journal of Alzheimer's Disease, 2022, 86, 1545-1567.	1.2	9
117	Relevance of Subjective Cognitive Decline in Older Adults with a First-Degree Family History of Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 87, 545-555.	1.2	5
118	Measuring Subjective Cognitive Decline in Older Adults: Harmonization Between the Cognitive Change Index and the Measurement of Everyday Cognition Instruments. Journal of Alzheimer's Disease, 2022, 87, 761-769.	1.2	0
119	Repetitive Transcranial Magnetic Stimulation for Alzheimer's Disease Based on Apolipoprotein E Genotyping: Protocol for a Randomized Controlled Study. Frontiers in Aging Neuroscience, 2021, 13, 758765.	1.7	5
120	Characteristics of subjective cognitive decline associated with amyloid positivity. Alzheimer's and Dementia, 2022, 18, 1832-1845.	0.4	22
125	Using Deep Learning Radiomics to Distinguish Cognitively Normal Adults at Risk of Alzheimer's Disease From Normal Control: An Exploratory Study Based on Structural MRI. Frontiers in Medicine, 2022, 9, 894726.	1.2	6
126	Mild Traumatic Brain Injury Is Related to Elevated Cerebrospinal Fluid Tau in Alzheimer's Disease Dementia. Journal of Alzheimer's Disease, 2022, 87, 1491-1496.	1.2	1
127	Changes in Adiposity and Cerebrospinal Fluid Biomarkers Following a Modified Mediterranean Ketogenic Diet in Older Adults at Risk for Alzheimer's Disease. Frontiers in Neuroscience, 2022, 16, .	1.4	5
128	Immunity gene <i>IFITM3</i> variant: Relation to cognition and Alzheimer's disease pathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, .	1.2	1
129	Order selection for regression-based hidden Markov model. Journal of Multivariate Analysis, 2022, 192, 105061.	0.5	3
130	Multimodal Self-Paced Locality-Preserving Learning for Diagnosis of Alzheimer's Disease. IEEE Transactions on Cognitive and Developmental Systems, 2023, 15, 832-843.	2.6	4
131	Tau levels are higher in objective subtle cognitive decline but not subjective memory complaint. Alzheimer's Research and Therapy, 2022, 14, .	3.0	3
132	How molecular imaging studies can disentangle disease mechanisms in age-related neurodegenerative disorders. , 2023, , 455-492.		0
133	Study Design and Baseline Results in a Cohort Study to Identify Predictors for the Clinical Progression to Mild Cognitive Impairment or Dementia From Subjective Cognitive Decline (CoSCo) Study. Dementia and Neurocognitive Disorders, 2022, 21, 147.	0.4	7
134	APOE Îμ4 genotype, amyloid-β, and sex interact to predict tau in regions of high APOE mRNA expression. Science Translational Medicine, 2022, 14, .	5.8	13
135	White matter hyperintensity load varies depending on subjective cognitive decline criteria. GeroScience, 2023, 45, 17-28.	2.1	7

#	Article	IF	CITATIONS
136	Effects of preventive interventions on neuroimaging biomarkers in subjects at-risk to develop Alzheimer's disease: A systematic review. Frontiers in Aging Neuroscience, 0, 14, .	1.7	2
137	Increase of ALCAM and VCAM-1 in the plasma predicts the Alzheimer's disease. Frontiers in Immunology, 0, 13, .	2.2	1
139	Auditory Event-Related Potentials in Older Adults with Subjective Memory Complaints. Journal of Alzheimer's Disease, 2023, 92, 1093-1109.	1.2	1
140	Neural correlates of subjective cognitive decline in adults at high risk for Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 15, .	1.7	0
141	Characteristics of Subjective Cognitive Decline Associated with Alzheimer's Disease Amyloid Pathology: Findings from The CABLE Study. Journal of Alzheimer's Disease, 2023, 92, 581-590.	1.2	1
142	Neuroimaging in Dementia. CONTINUUM Lifelong Learning in Neurology, 2023, 29, 219-254.	0.4	1
143	The use of hippocampal grading as a biomarker for preclinical and prodromal Alzheimer's disease. Human Brain Mapping, 2023, 44, 3147-3157.	1.9	5
144	Functional MRI Studies of Memory in Aging, Mild Cognitive Impairment, and Alzheimer's Disease. , 2023, 671-712		0